<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159142</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-KAL-BC-16</org_study_id>
    <nct_id>NCT04159142</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer</brief_title>
  <official_title>Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The fifth medical center of PLA general hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a
      term applied to breast cancer cases that have &lt;1% expression of the estrogen receptor (ER)
      and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20%
      of breast cancer cases and tends to occur in younger women and have biologically more
      aggressive high grade disease.

      The purpose of this study is to assess the efficacy and safety of the following two
      combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with
      advanced TNBC and up to one prior line of systemic treatment for metastatic disease.
      Maintenance therapy with capecitabine after completion of combination chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2019</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Up to disease progression or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS rate for 6 cycles</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 21 days)</time_frame>
    <description>From the date of randomization to the end of 6 cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the Overall Response Rate of patients with advanced triple-negative breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the overall survival of patients with advanced triple-negative breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the adverse events of patients with advanced triple-negative breast cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Nab-paclitaxel</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nab-paclitaxel + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel + Carboplatin</intervention_name>
    <description>nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；</description>
    <arm_group_label>Nab-paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel + Capecitabine</intervention_name>
    <description>Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles；</description>
    <arm_group_label>Nab-paclitaxel + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with age between 18 to 70 years old;

          2. Histologically confirmed triple negative breast cancer;

          3. No more than one-line prior treatment for locally advanced or metastatic breast
             cancer;

          4. Have at least one measurable lesion as per the RECIST criteria (version 1.1);

          5. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
             one;

          6. Patients with life expectancy of at least 3 months;

          7. Bone marrow function：neutrophils (≥1.5×10^9/L), platelets (≥100×10^9/L), hemoglobin
             (≥90 g/L);

          8. Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal
             (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert's
             syndrome ≤ 2.5 × ULN;

          9. Patients had good compliance with the planned treatment, understood the research
             process and written informed consent.

        Exclusion Criteria:

          1. Patients with heart disease above grade II (including grade II) identified by New York
             Heart Association (NYHA) scores;

          2. Brain metastasis;

          3. Recurrence or metastasis within 6 months after capecitabine withdrawal;

          4. Recurrence or metastasis within 6 months after platinum withdrawal;

          5. Progression in the treatment, recurrence or metastasis of paclitaxel (including
             albumin paclitaxel) within 6 months;

          6. Patients required clinical intervention with gastrointestinal bleeding,
             gastrointestinal obstruction and non-feeding;

          7. Patients who had Grade 2 or above Peripheral neuropathy;

          8. Patients with severe systemic infection or other serious diseases;

          9. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;

         10. Patients with other malignant tumors in the past five years, except for cured cervical
             carcinoma in situ and non-melanoma skin cancer;

         11. Pregnancy or lactation, as well as reproductive age patients who refused to take
             appropriate contraceptive measures in the trial;

         12. Participation in any trial drug treatment or another interventional clinical trial 30
             days before first dose was given;

         13. The researchers considered the patients who were not suitable for enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefei Jiang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The fifth medical center of PLA general hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cuizhi Geng, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Fourth Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cuizhi Geng, M.D.</last_name>
    <phone>0311-6669 6310</phone>
    <email>gengcuizhi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cuizhi Geng, M.D.</last_name>
      <phone>0311-6669 6310</phone>
      <email>gengcuizhi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Cuizhi GENG</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Maintenance therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

